Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

IL-4 fusion toxin shows potent antitumor activity in murine model of KS

July 10, 1998

NeoPharm scales up IL13-PE38QQR manufacturing

July 10, 1998

GOG will evaluate Avax Technologies' ovarian cancer vaccine in phase I/II study

July 6, 1998

Herceptin licensed to Roche for most markets

July 6, 1998

Phase II retreatment trial with Bexxar commences

June 30, 1998

Schering-Plough acquires Canadian rights to Ribi's melanoma theraccine

June 29, 1998

Orphan drug status granted to Endorex's ImmTher for Ewing's sarcoma

June 29, 1998

CMB-401, an immunoconjugate for the targeted treatment of EOC

June 25, 1998

Positive phase II results for GMK vaccine presented at NCI-EORTC meeting

June 25, 1998

NeoRx begins phase I trial of Pretarget technology in lymphoma

June 25, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...